A commons-based approach opens new doors to scientific discovery. The publications below represent the collective efforts of PCDC disease consortia. In addition, the PCDC has published several papers about the potential applications of data sharing in pediatric cancer research. Read more about these publications here.
Click each consortium name to expand the list of publications.
- Chennakesavalu M, Pudela C, Applebaum MA, et al. Persistence of Racial and Ethnic Disparities in Risk and Survival for Patients with Neuroblastoma over Two Decades. EJC Paediatr Oncol. Epub 2023 Jul 10.
- Campbell K, Kao PC, Naranjo A, et al. Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2023 Feb;70(2):e30054. Epub 2022 Oct 31.
- Vo KT, DuBois SG, Neuhaus J, et al. Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2022 Feb;e29616.
- Bao R, Spranger S, Hernandez K, et al. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. J Immunother Cancer. 2021 Jul;9(7):e002417.
- Balyasny S, Lee SM, Desai AV, et al. Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Netw Open. 2021 Jul 1;4(7):e2116248.
- Moreno L, A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high‐risk neuroblastoma: An International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2021;68(3):e28794. , , et al.
- The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2020;67(8):e28359. , , , et al.
- Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2019;66(8):e27819. , , , et al.
- Applebaum MA, Vaksman Z, Lee SM, et al. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2017;72:177-185.
- Thompson D, Vo KT, London WB, et al. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. Cancer. 2016;122:935-945.
- Morgenstern DA, London WB, Stephens D, et al. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Eur J Cancer. 2016; 65:1-10.
- Vo KT, Matthay KK, Neuhaus J, et al. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2014;32(28):3169-76.
- Meany HJ, London WB, Ambros PF, et al. Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer, 2014:61(11):1932-1939.
- Mossé YP, Deyell RJ, Berthold F, et al. Neuroblastoma in older children, adolescents and young adults: A report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014;61(4):627-635.
- Morgenstern DA, London WB, Stephens D, et al. Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database. J Clin Oncol. 2014;32(12):1228-35.
Additional INRG publications preceding the launch of the data commons, as well as INRG Task Force consensus papers, may be found on the INRG website.
INRG Presentations
- Angelini P, Vaidya S, Okoye B, Pearson A, London W. Ganglioneuroma (GN) and Intermixed ganglioneuroblastoma (iGNB): characteristics at diagnosis, natural history and outcome. Presented at Advances in Neuroblastoma Research Webinars; 2021.
- Mayampurath A, Volchenboum S, Cohn S, Applebaum M. Predicting induction chemotherapy response using deep learning. Presented at American Society of Clinical Oncology; 2021.
- Pudela C, Desai A, Applebaum M, Henderson T, Cohn S. Racial and Ethnic Disparities in Risk and Survival in Children With Neuroblastoma: An Updated Analysis Using the International Neuroblastoma Risk Group Database. Presented at American Society of Clinical Oncology; 2021.
- Kirby C, Andrade J, Huang L, et al. Gene expression analysis of neuroblastoma tumors according to MKI and differentiation status. Presented at Advances in Neuroblastoma Research; 2014; Cologne, Germany.
- Schoot RA, van Ewijk R, von Witzleben A, et al. INternational Soft Tissue saRcoma ConsorTium (INSTRuCT) Consensus Statement: Imaging Recommendations for the Management of Rhabdomyosarcoma. Eur J Radiol. Epub 2023 Jul 25.
- Sparber-Sauer M, Ferrari A, Spunt SL, et al. The significance of margins in pediatric Non-Rhabdomyosarcoma soft tissue sarcomas: Consensus on surgical margin definition harmonization from the INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT). Cancer Med. Epub 2023 Feb 6.
- Schoot RA, Ferrari A, von Kalle T, et al. Imaging recommendations for the management of pediatric non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): Consensus statement of the International Soft Tissue Sarcoma Consortium (INSTRuCT). EJC Paediatr Oncol. 2023;1:100008.
- Hettmer S, Linardic CM, Kelsey A, et al. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children’s Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. Eur J Cancer. 2022;172:367-386.
- Casey DL, Mandeville H, Bradley JA, et al. Local control of parameningeal rhabdomyosarcoma: An expert consensus guideline from the International Soft Tissue Sarcoma Consortium (INSTRuCT). Pediatr Blood Cancer. 2022;69(7):e29751.
- Ferrari A, Orbach D, Sparber-Sauer M, et al. The treatment approach to pediatric non-rhabdomyosarcoma soft tissue sarcomas: a critical review from the INternational Soft Tissue SaRcoma ConsorTium. Eur J Cancer. 2022;169:10-19.
- Ferrari A, Spunt SL, Sparber-Sauer M, et al. Controversies and challenges in the management of paediatric non-rhabdomyosarcoma soft tissue sarcomas. Lancet Child Adolesc. Health. 2022;6(3).
- Rogers TN, Seitz G, Fuchs J, et al. Surgical management of paratesticular rhabdomyosarcoma: A consensus opinion from the Children’s Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer. 2021;68(4):e28938.
- Rudzinski ER, Kelsey A, Vokuhl C, et al. Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children’s Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer. 2021;68(3):e28798.
- Hawkins DS, Bisogno G, Koscielniak E. Introducing INSTRuCT: An international effort to promote cooperation and data sharing. Pediatr Blood Cancer. 2023 Mar;70(3):e28701. Epub 2020 Sep 12.
- Morris CD, Tunn P, Rodeberg DA, et al. Surgical management of extremity rhabdomyosarcoma: A consensus opinion from the Children’s Oncology Group, the European Pediatric Soft‐Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer. 2023 Mar;70(3):e28608. Epub 2020 Aug 9.
- Lautz TB, Martelli H, Fuchs J, et al. Local treatment of rhabdomyosarcoma of the female genital tract: Expert consensus from the Children’s Oncology Group, the European Soft‐Tissue Sarcoma Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer. 2023 May;70(5):e28601. Epub 2020 Aug 6.
- Fonseca A, Lobo J, Hazard FK, et al. Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium. Br J Cancer. 2022 Oct;127:1577–1583.
- Pashankar F, Hanley K, Lockley M, et al. Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference. Eur J Cancer. 2022 Sep;173:59-70.
- Singla N, Wong J, Singla S, et al. Clinicopathologic predictors of outcome in children with stage 1 testicular germ cell tumors: A pooled post hoc analysis of trials from the Children’s Oncology Group. J Pediatr Urol. 2022 May.
- Kobayashi M, Kobayashi M, Odajima J, et al. Expanding homogeneous culture of human primordial germ cell-like cells maintaining germline features without serum or feeder layers. Stem Cell Reports. 2022 Mar;17(3):507–521.
- Skowrona MA, Oing C, Bremmer F, et al. The Developmental Origin of Cancers Defines Basic Principles of Cisplatin Resistance. Cancer Letters. 2021 Oct;519:199-210.
- Piao J, Lafin JT, Scarpini CG, et al. A multi-institutional pooled analysis demonstrates that circulating miR-371a-3p alone is sufficient for testicular malignant germ cell tumor diagnosis. Clin Genitourinary Cancer. 2021 Sep;19(6):469-479.
- Billmire D, Dicken B, Rescorla F, et al. Imaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant Histology. J Pediatr Adolesc Gynecol. 2021 Jun;34(3):383-386.
- Weil B, Billmire D. Management of Germ Cell Tumors in Pediatric Patients. Surg Oncol Clin N Am. 2021 Apr;30(2):325-338.
- Shaikh F, Stark D, Fonseca A, et al. Outcomes of Adolescent Males with Extracranial Metastatic Germ Cell Tumors: A Report From the Malignant Germ Cell Tumor International Consortium. Cancer. 2021 Jan 15;127(2):193-202.
- Bo Ci B, Yang DM, Krailo M, et al. Development of a Data Model and Data Commons for Germ Cell Tumors. JCO Clin Cancer Inform. 2020 Jun;4:555-566.
- Veneris J, Mahajan P, Frazier AL. Contemporary Management of Ovarian Germ Cell Tumors and Remaining Controversies. Gynecol Oncol. 2020;158(2):467-475.
- Murray MJ, Ajithkumar TV, Harris F, et al. Clinical Utility of Circulating miR-371 a-3p for the management of patients with Intracranial Malignant Germ Cell Tumors. Neurooncology Adv. 2020;2(1):vdaa048.
- Lafin J, Singla N, Woldu S, et al. A Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection. Eur Urol. 2020;77(2):290-292.
- Xu L, Pierce JL, Sanchez A, et al. Integrated genomic analysis reveals aberrations in WNT signaling in germ cell tumors of childhood and adolescence. Eur Urol Supplements. 2019;18(4):13-14.
- Fonseca A, Frazier AL, Shaikh F. Germ Cell Tumors in Adolescents and Young Adults. J Oncology Pract. 2019;15(8):433-441.
- Depani S, Stoneham S, Krailo M, Xia C, Nicholson J. Results from the UK Children’s Cancer and Leukaemia Group study of extracranial germ cell tumours in children and adolescents (GCIII). Eur J Cancer. 2019;118:49-57.
- O’Neill AF, Xia C, Krailo M, et al. α-Fetoprotein as a Predictor of Outcome for Children With Germ Cell Tumors: A Report From the Malignant Germ Cell International Consortium. Cancer. 2019;125(20):3649-3656.
- Murray MJ, Coleman N. Can circulating microRNAs solve clinical dilemmas in testicular germ cell malignancy? Nat Rev Urol. 2019;16:505–506.
Additional MaGIC publications preceding their partnership with the PCDC may be found on their website.